IQVIA (NYSE:IQV - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday, Wall Street Zen reports.
A number of other brokerages also recently issued reports on IQV. Weiss Ratings downgraded IQVIA from a "hold (c+)" rating to a "sell (d+)" rating in a report on Wednesday, October 28th. Barclays raised their price target on IQVIA from $275.00 to $300.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Jefferies Financial Group raised their price target on shares of IQVIA from $220.00 to $290.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Rothschild & Co Redburn raised their target price on shares of IQVIA from $284.00 to $287.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Finally, HSBC lifted their target price on shares of IQVIA from $280.00 to $300.00 and gave the company a "buy" rating in a report on Tuesday, September 1st. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $294.21.
Read Our Latest Analysis on IQV
IQVIA Stock Down 1.9%
IQV opened at $245.68 on Friday. The firm's 50 day simple moving average is $267.01 and its two-hundred day simple moving average is $212.56. The company has a market capitalization of $40.49 billion, a PE ratio of 22.86, a PEG ratio of 2.35 and a beta of 1.16. IQVIA has a 1-year low of $154.50 and a 1-year high of $284.50. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 2.18.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, beating the consensus estimate of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The business had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter in the prior year, the firm earned $3.00 EPS. The business's revenue was up 8.0% on a year-over-year basis. As a group, equities analysts forecast that IQVIA will post 11.53 EPS for the current year.
Insider Buying and Selling
In related news, insider James G. Berkshire sold 2,668 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares of the company's stock, valued at $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Sherbet sold 4,446 shares of the firm's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the transaction, the insider owned 24,989 shares in the company, valued at $6,967,682.87. This represents a 15.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.70% of the company's stock.
Institutional Investors Weigh In On IQVIA
Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in IQVIA during the 2nd quarter worth approximately $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in IQVIA by 9.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company's stock valued at $315,772,000 after buying an additional 134,997 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in IQVIA during the second quarter worth approximately $240,911,000. Bank of America Corp DE purchased a new stake in IQVIA during the second quarter worth approximately $235,551,000. Finally, Legal & General Group Plc purchased a new stake in IQVIA during the second quarter worth approximately $211,342,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.
IQVIA Company Profile
(
Get Free Report)
IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company's offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.